Cargando…
Current and Novel Inhibitors of HIV Protease
The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, sid...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185513/ https://www.ncbi.nlm.nih.gov/pubmed/21994591 http://dx.doi.org/10.3390/v1031209 |
_version_ | 1782213222881820672 |
---|---|
author | Pokorná, Jana Machala, Ladislav Řezáčová, Pavlína Konvalinka, Jan |
author_facet | Pokorná, Jana Machala, Ladislav Řezáčová, Pavlína Konvalinka, Jan |
author_sort | Pokorná, Jana |
collection | PubMed |
description | The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed. |
format | Online Article Text |
id | pubmed-3185513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-31855132011-10-12 Current and Novel Inhibitors of HIV Protease Pokorná, Jana Machala, Ladislav Řezáčová, Pavlína Konvalinka, Jan Viruses Review The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed. Molecular Diversity Preservation International (MDPI) 2009-12-11 /pmc/articles/PMC3185513/ /pubmed/21994591 http://dx.doi.org/10.3390/v1031209 Text en © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Pokorná, Jana Machala, Ladislav Řezáčová, Pavlína Konvalinka, Jan Current and Novel Inhibitors of HIV Protease |
title | Current and Novel Inhibitors of HIV Protease |
title_full | Current and Novel Inhibitors of HIV Protease |
title_fullStr | Current and Novel Inhibitors of HIV Protease |
title_full_unstemmed | Current and Novel Inhibitors of HIV Protease |
title_short | Current and Novel Inhibitors of HIV Protease |
title_sort | current and novel inhibitors of hiv protease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185513/ https://www.ncbi.nlm.nih.gov/pubmed/21994591 http://dx.doi.org/10.3390/v1031209 |
work_keys_str_mv | AT pokornajana currentandnovelinhibitorsofhivprotease AT machalaladislav currentandnovelinhibitorsofhivprotease AT rezacovapavlina currentandnovelinhibitorsofhivprotease AT konvalinkajan currentandnovelinhibitorsofhivprotease |